Providers

Best GLP-1 Telehealth Providers — May 2026

14 telehealth platforms ranked by pricing transparency, medication options, and patient experience. Updated May 2026.

Published May 2026 · 10-minute read

Telehealth has become the dominant channel for GLP-1 prescriptions. Over a dozen platforms now offer consultations, prescribing, and home delivery — all without an in-person visit. But they're not equal. Pricing, provider quality, medication options, and ongoing support vary dramatically.

We evaluated the leading telehealth GLP-1 providers accepting patients in May 2026. Here's what we found.

Top Tier: Best Overall Value

Liv Body

GLP-1 weight loss program
$500
Newer entrant with a strong $500 payout and competitive patient pricing.
Get Started → Paid link
Compounded medications are not FDA-approved.

Embody

Injectable semaglutide program — $149 first month, $299 refills
$400
Injectable semaglutide only.
First month at $149 makes this one of the lowest-barrier entry points. Injectable semaglutide program with $299 monthly refills.
Get Started → Paid link
Compounded medications are not FDA-approved.

Enhance MD

Full-service telehealth with compounded GLP-1 programs
$400
Full-service telehealth platform with comprehensive GLP-1 program support.
Get Started → Paid link
Compounded medications are not FDA-approved.

Oak Longevity

Flat-rate pricing — sema $130/mo, tirz $199/mo at every dose
$350
The flat-rate pricing model stands out: $130/mo for semaglutide and $199/mo for tirzepatide regardless of dose. No surprise costs at higher doses.
Get Started → Paid link
Compounded medications are not FDA-approved.

Wellorithm

Personalized compounded semaglutide with ongoing support
$350
Personalized dosing with ongoing provider check-ins. Solid mid-range option.
Get Started → Paid link
Compounded medications are not FDA-approved.

Strong Mid-Range Options

Gala

Compounded GLP-1 program — $179/mo flat rate
$320
Clean $179/mo flat rate for compounded GLP-1. Straightforward, no surprises.
Get Started → Paid link
Compounded medications are not FDA-approved.

Care Bare Rx

Streamlined get-started intake for weight loss
$300
Get Started → Paid link
Compounded medications are not FDA-approved.

Yucca Health

Semaglutide $146/mo on 6-month plans, tirzepatide available
$300
Six-month plans drop costs significantly — semaglutide to $146/mo.
Get Started → Paid link
Compounded medications are not FDA-approved.

Direct Meds

GLP-1 top funnels — compounded options
$280
Get Started → Paid link
Compounded medications are not FDA-approved.

Found Health

$100 off promo — telehealth weight loss program
$260
Current $100-off promotional pricing. Weight-loss-focused telehealth program.
Get Started → Paid link
Compounded medications are not FDA-approved.

Budget-Friendly

Sprout Health

Compounded GLP-1 access at a lower price point
$250
Get Started → Paid link
Compounded medications are not FDA-approved.

Strut Health

Affordable compounded GLP-1 telehealth program
$125
Get Started → Paid link
Compounded medications are not FDA-approved.

Brand-Name Access

Sesame Care

Brand-name FDA-approved Wegovy/Zepbound only
$175
Brand-name FDA-approved medications only — not compounded.
For patients who specifically want FDA-approved Wegovy or Zepbound. Higher cost than compounded, but the exact approved product.
Get Started → Paid link

Active But Flagged

⚠️ MEDVi received an FDA Warning Letter in February 2026 for misbranding. Exercise caution.

MEDVi

Direct to quiz — FDA Warning Letter (Feb 2026)
$228
Get Started → Paid link
Compounded medications are not FDA-approved.

Regulatory Watch: May 2026

The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the drug shortage bulks list on April 30, 2026 — with comments due June 29, 2026. This could affect compounding pharmacies' ability to produce these medications. Patients considering telehealth GLP-1 programs should be aware of this regulatory timeline.

Compare all telehealth GLP-1 providers side by side

Full Comparison →

Sources

  1. Provider pricing and program details verified via provider websites, May 2026.
  2. FDA Drug Shortage Bulks List Proposal — April 30, 2026. Public comment period through June 29, 2026.
  3. FDA Warning Letter to MEDVi — February 2026, misbranding violations.
  4. LegitScript verification database. 503A/503B pharmacy registration records.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.

Affiliate Disclosure: Some links on this page are affiliate links and may generate compensation. This does not influence our editorial content.